

CURRICULUM VITAE

Fu-Dong Shi, M.D., Ph.D., MAE

PERSONAL DATA:

Name: Fu-Dong Shi
Gender: Male
Profession: Neurologist, M.D, Ph.D
Nationality: United States of America
Residence: Beijing, Tianjin, China; San Diego, California
Web information: <http://bjtjcn.com/research/people/1/>
Email: fshi@tmu.edu.cn



CURRENT POSITIONS

Professor and Chair, Chief Neurologist, Division of Neuroimmunology, Beijing-Tianjin Center for Neuroinflammation (BTCN), Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, China

Professor and Chairman, Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China;

Vice president, Tianjin Medical University General Hospital;

Visiting Professor, Department of Neurology, Experimental and Clinical Research Center (ECRC) at Charité – Universitätsmedizin Berlin, Germany

EDUCATION

1984 – 1989 M.D. Clinical Medicine, Harbin Medical College and Peking Union Hospital, Beijing and Harbin, China
1989 – 1995 Neurology Resident, Department of Internal Medicine and Neurology, The Second Hospital, Harbin Medical University, Harbin, China. Supervisors: Professors Wei Zhi Wang and Peng Zhang.
1995 – 1999 Ph.D. Candidate, Division of Neurology, Karolinska Institute, Stockholm, Sweden
Supervises: Professors Hans Link and Hans-Gustaf Ljunggren;
Thesis: Immunopathogenesis and nasal tolerance in myasthenia gravis.
1999 – 2003 Post-Doctoral Fellow, Immunology, The Scripps Research Institute, La Jolla, California, USA
Supervisors: Professors Nora Sarvetnick and Eng M. Tan.

APPOINTMENT

1995 Attending Neurologist, Department of Neurology, The Second Hospital, Harbin Medical University, Harbin, China
2003 – 2007 Assistant Professor of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA

2007 – 2010	Associate Professor of Neurology (with tenure), Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA
2010 – 2020	Adjunct Professor of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA
2010 – Present	Professor and Chairman, Department of Neurology, Tianjin Medical University General Hospital, Tianjin 300052, China.
2014 – Present	Vice President, Tianjin Medical University General Hospital, Tianjin 300052, China.
2018 – Present	Director, Chief Neurologist, Beijing-Tianjin Center for Neuroinflammation (BTCN), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2023– Present	Visiting Professor, Department of Neurology, Experimental and Clinical Research Center (ECRC) at Charité – Universitätsmedizin Berlin, Germany
2023– Present	Professor and Chair, Chief Neurologist, Division of Neuroimmunology, Beijing Tiantan Hospital, Beijing, China

PROFESSIONAL QUALIFICATIONS

- Research Neurologist, Barrow MS Clinic, Phoenix, AZ, USA 2003-2010; USMLEs and ECFMG CERTIFICATE
- ECFMG CERTIFICATE AND SERIAL#: 6-9-2008, 0-710-829-3
- US Neurology Resident Match Contract#: 911.50 Barrow N.I. Phoenix
- EDSS and FS: 12-16-2004
- Chinese Neurologist Qualification and License# 199812110230103; 110120000030094

NATIONAL AND INTERNATIONAL ACADEMIC ACTIVITIES

- 2001 – American Association of Immunology
- 2005 – American Neurological Association
- 2014 – 2020 President, Tianjin Neurological Association
- 2015 – 2023 Member, Central Organizing Committee, Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS)
- 2015 – Member, American Heart Association
- 2016 – 2023 Director, Tianjin Stroke Association
- 2018 – Chair, China Medical Network for Neuroinflammation (CMNN)
- 2018 – 2020 Scientific Chair, Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS)
- 2018 – Editorial Board, *Science Translational Medicine*
- 2020 – Chair, Neuroimmunology Section, Chinese Neurological Association
- 2022 – Chair, Neuroimmunology Section Chinese Society for Immunology

- 2023 – Chair, Stroke Immunology Section, Chinese Stroke Association
- 2023 – Member, European Charcot Foundation Board (ECF)
- 2024 – Editorial Board, *Cell Death & Differentiation*
- 2024 – Member of The Academy of Europe, Physiology and Neuroscience

GRANTS REVIEW:

- 2008 – 2018 National Institute of Health (NIAID): Ad Hoc members for special panels of Autoimmune Centers of Excellence U19; Ancillary Studies in Immunomodulation Clinical Trials; Hypersensitivity, Allergy and Immune Mediated Disease ZRR1; Cooperative Study Group for Autoimmune Disease Prevention; Transplantation, Tolerance, & Tumor Immunology; Allergy, Immunology, and Transplantation Research; Special Emphasis Panels: ZRG1 IMM-K02 and Autoimmunity Center of AI-14-012/013; NIDDK, ZRG1 IMM-R. CNBT: Clinical Neuroimmunology and Brain Tumor.
- 2005 – Present Welcome Trust, Italian MS Society, Swedish MS Society.
- 2012 – Present National Natural Science Found of China; Ministry of Science and Technology of China.

JOURNALS REVIEW:

Frequent Reviews for: *Nature Medicine*, *Nature Immunology*, *PNAS*, *Immunity*, *Journal of Clinical Investigation*, *Journal of Immunology*, *Neurology*, *JAMA Neurology*, *Brain*, *Neuron*, *Journal of Experimental Medicine*, *Lancet Neurology*, *JAMA Neurology*, *New England Journal of Medicine*

Editorial Service: *Cell Death & Differentiation* (Editorial Board, since 2024), *Science Translational Medicine* (Editorial Board, since 2018); *Neuroscience Bulletin* (Associate Editor, since 2015), *CNS Neuroscience & Therapeutics* (Associate Editor, since 2016); *Stroke and Vascular Neurology* (Associate Editor, since 2023).

HONORS AND AWARDS

- 2000 Postdoctoral Fellowship Award from Juvenile Diabetes Foundation International
- 2004 Development Award, US Muscular Dystrophy Association •
- 2009 Chang Jiang Scholar Award Program, Ministry of Education, China
- 2011 1000 Talent Recruit Program of China, Chinese Central Government
- 2015 China Stroke Award for Innovation Research, China Stroke Association
- 2016 Tianjin Distinguished Talent Award

- 2017 Outstanding Neurologist of China, Chinese Neurologist Association
- 2017 China Stroke Award; Chinese Stroke Association.
- 2019 Tianjin Municipal Award for Excellence in Science & Technology
- 2021 Beijing Municipal Award for Exceptional Scientific Innovation
- 2023 Beijing Municipal Award for Excellence in Science & Technology

PATENTS (acquisition of 28 China and international patents, examples are below)

- Creation of FPR1 antagonist for treatment of atherosclerosis (China ZL202210782507.1; Patent Date: July 28, 2023; PCP, pending). Primary inventor: Fu-Dong Shi.
- Generation of biomarkers for prognostic assessment of intracerebral hemorrhage (China ZL202110837328.9; Patent Date: July 8, 2022). Primary inventor: Fu-Dong Shi.
- Generation of biomarkers for detection or recurrence monitoring of neuromyelitis optica spectrum disorder (China ZL202110911380.4; Patent Date: Nov 30, 2021). Primary inventor: Fu-Dong Shi.
- Method and drug for alleviating hemorrhagic transformation after rtPA administration (China ZL201910335185.4; Patent Date: June 11, 2021). Primary inventor: Fu-Dong Shi.
- Method for detecting formyl peptide or formyl peptide receptor-1 ligand (China ZL202010322743.6; Patent Date: Apr 6, 2021). Secondary inventor: Fu-Dong Shi.
- Method and drug for prolonging thrombolytic time window of ischemic stroke (China ZL201711336661.1; Patent Date: Apr 10, 2020). Primary inventor: Fu-Dong Shi.
- Nicotine attenuates the central nervous system inflammation and autoimmunity (US 8,841,329 B2; Patent Date: Sep 23, 2014). Primary inventor: Fu-Dong Shi.

ENTREPRENEUR ACTIVITIES:

- New Terrain, a Tianjin, China based biotech with expertise in immunodiagnostic technologies, products and services. Founded in 2018. Roles: co-founder and advisor;
- AKRIVA, a Jiangsu Province, China based biotech with expertise in immunodiagnostic technologies, products and services. Founded in 2023. Roles: co-founder and advisor;
- Scientific Advisory Board: Roche, Sanofi, UCB, Novartis, Biogen.

FUNDING HISTORY

US funding

- NIH R01 NS105730-01A1 (Shi, PI; transferred to co-I) 2018 – 2022 S1PR
Modulation in Intracerebral Hemorrhage, Percentile: 2
Total fund: \$ 2,171,829
- NIH R01 NS107189-01 (Shi, PI; transferred to co-I) 2018 – 2022 Natural
killer cells in intracerebral hemorrhage, Percentile: 9
Total fund: \$ 2,233,654

- NIH R01 NS092713 (Shi, PI) 2016 – 2021 Stroke
induced-NK cell deficiency: mechanisms and clinical implications
Total fund: \$ 2,030,205
- National Multiple Sclerosis Society (Shi, PI) 2016 – 2019
Neurorepair following brain inflammation
Total fund: \$ 173,000
- NIH R01 NS082745 (Sanai, PI; Shi, Co-PI) 2014 – 2018 Molecular
mechanisms underlying glioma invasion of the human SVZ
- NIH R01 NIAID AI083294 (Shi, PI) 2010 – 2015 NK cells
in CNS inflammation and autoimmunity
Total fund: \$ 1,995,628
- American Heart Association 14GRNT18970031 (Shi, PI) 2014 – 2015
Recruitment of natural killer cells by ischemic neurons
- Barrow Neuroimmunology Program Endowed funding (Shi, PI) 2004 – 2010
\$50,000/year for consecutive six years
- Muscular Dystrophy Association Development Grant (Shi, PI,) 2002 – 2009
\$65,000/year for consecutive seven years
- Juvenile Diabetes Foundation Post Doctorial Fellowship (Shi, PI) 2000 – 2002
Total fund: \$ 90,000

Fellowship mentored

Served as mentor or co-mentor for the following trainees (after completion of these fellowships, each of these trainees has become faculty of Universities in the Europe US, Canada and China)

- Marlin Flodstrom, Ph.D.
Juvenile Diabetes Foundation: Virus induced diabetes
\$ 47,000/year 2003 – 2005
Currently: Professor, Division of Neurology, Huddinge Hospital, Karolinska Institute
- Ruolan Liu, M.D., Ph.D.
Muscular Dystrophy Association: Treg cell in myasthenia
\$ 56,000/year 2004 – 2006
Currently: Associate Professor, Department of Molecular Medicine, University of Kentucky
- Alain Simard, Ph.D.
National Multiple Sclerosis Society: Nicotinic receptor $\alpha 7$ in CNS autoimmunity
\$48,000/year 2004 – 2008
Currently: Associate Professor, Department of Medicine, University of Toronto
- Andrew Ducruet, M.D.
American Heart Association: Brain edema after intracerebral hemorrhage
\$ 73,000/year 2006 – 2008
Currently: Associate Professor, Attending Neurosurgeon, Barrow Neurological Institute
- Qiang Liu, Ph.D.
American Heart Association Development Award: Immune mechanisms of stroke
\$ 68,000/year 2004 – 2007

- JunWei Hao, M.D., PhD.
National Science Foundation for Distinguished Young Scholars (杰青): Neuroinflammation in neurological diseases
Total fund: ¥ 4,000,000 2018 - 2022
Currently: Professor and Chairman, Vice President, Beijing Xuan Wu Hospital, Beijing, China
- Cunjin Zhang, M.D., PhD.
National Science Foundation for Excellent Young Scientists (优青): Th17 differentiation in experimental autoimmune encephalomyelitis
Total fund: ¥ 1,200,000 2021 - 2023
Currently: Professor of Neurology, Sichuan Provincial Hospital, Chengdu, Sichuan Province, China
- Weina Jin, Ph.D.
National Science Foundation for Excellent Young Scientists (优青): Aging and brain inflammation
Total fund: ¥ 2,000,000 2022 - 2024
Currently: Associate Professor, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital,
Capital Medical University, Beijing, China
- Kaibin Shi, M.D., Ph.D.,
National Science Foundation for Excellent Young Scientists (优青): Neuroinflammation and stroke
Total fund: ¥ 2,000,000 2024 - 2026
Currently: Attending Neurologist, Department of Neurology, Beijing Tiantan Hospital, Beijing, China

Chinese funding

- National Science Foundation of China, International Cooperation and Exchange 82320108007 (Shi, PI)
Bruton tyrosine kinase in neuromyelitis optica spectrum disease
Total fund: ¥ 2,100,000 2024 - 2028
- National Science Foundation of China, Major Research Plan 91949208 (Shi, PI)
Natural killer cells in normal brain aging
Total fund: ¥ 2,050,000 01/2020 - 12/2023
- National Science Foundation of China, Key Program 81830038 (Shi, PI)
Microglia and Brain Edema after Intracerebral Hemorrhage
Total fund: ¥ 3,000,000 01/2019 - 12/2022
- Ministry of Science and Technology of China, National Key Research and Development Program (Shi, Co-PI)
Mechanisms and intervention evaluation of intracerebral hemorrhage
Total fund: ¥ 3,260,000 01/2018 - 12/2021
- Brain Protection Advanced Innovation Center, Beijing Municipal Education Commission Special Fund (Shi, PI)
- Science and technology innovation service capacity building project
Total fund: ¥ 5,000,000 01/2018 - 12/2020
- National Science Foundation of China, Major Research Plan 91642205 (Shi, PI)
Impact of ischemic brain injury on the immune system: organ-specific factors and mechanisms of action
Total fund: ¥ 2,000,000 01/2017 - 12/2021
- Ministry of Science and Technology of China, Major Project of Chinese National Programs (973 program; Shi, PI)
Immunogenicity and immune tolerance resulting from stem cell differentiation
Total fund: ¥ 29,000,000 01/2013 - 12/2017

- National Science Foundation of China, Key Program 81230028 (Shi, PI)
Reciprocal interactions between natural killer cell and neural stem cell in CNS inflammation
Total fund: ¥ 3,000,000 01/2013 - 12/2017
- National Science Foundation of China, General Program 31170864 (Shi, PI)
Thymic expression of Th17 initiates autoimmunity and relevant new immune targeted strategy
Total fund: ¥ 100,000 01/2012 - 12/2012

TRAINEES

Mentored 21 neurologists, 10 of them have become chief neurologist; 27 Ph.D students, 9 of them have become tenured professors in China, US, Canada and Europe.

INVITED PRESENTATIONS (total 348 presentations during 2003-2023)

- | | |
|---------------|---|
| Sep 18, 2023 | Stroke-Immunology Meeting-3 rd EMBO Workshop, Munich, Germany.
Plenary seminar: Colchicine in acute ischemic stroke and TIA: outcome of the CHANCE III trial |
| July 5, 2022 | ECF Mystery Solved Project - Baveno, Italy. |
| Nov 26, 2021 | 13th PACTRIMS Congress 2021
Thematic: Current treatment landscape and potential of B-cell therapy in China. |
| Oct 31, 2021 | FIMSA 2021---8th Congress of the FIMSA (Federation of Immunological Societies of Asia Oceania)
Thematic: Compartmental features of B cells in NMOSD |
| Oct 3, 2021 | The 25th World Congress of Neurology
Thematic: Update on clinical aspects of NMOSD and MOGAD |
| July 13, 2021 | FASEB SRC translational session, Paris, France
Thematic: Modulating brain inflammation: compartment, timing and drug selection |
| Apr 1, 2021 | 1st International Stroke-Immunology Meeting, Munich, Germany
Thematic: Results and ongoing activities on Fingolimod on Stroke |
| Jun 12, 2020 | China Myasthenia Gravis Forum Series
Thematic: MG Incidence in China and Current State of Management. |
| Feb 19, 2020 | International Stroke Conference 2020, Los Angeles. |
| Nov 13, 2019 | The 12th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Singapore.
Thematic: Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO trial): a head-to-head comparative study. |
| Oct 12, 2019 | The 2nd Asia Pacific School of Neuroimmunology (APSNI), Korea.
Thematic: Adaptive immunology in neurologic diseases. |
| Sep 11, 2019 | The 35th congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS (Ectrimis), Sweden.
Thematic: Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): a head-to-head comparative study. |

- Mar 28, 2019 The 13th Biennial Convention of the ASEAN NEUROLOGICAL ASSOCIATION (ASNA 2019), Myanmar.
Thematic: Neuromyelitis optica spectrum disorder (NMOSD): perspectives from Asian neurologists.
- Feb 14, 2019 The 5th International Porto Congress of Multiple Sclerosis, Porto, Portugal.
Thematic: MS and related disorders in China.
- Nov 01, 2018 The 11th Congress of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, (PACTRIMS), Sydney, Australia.
Thematic: Prospect of artificial intelligence in the management of MS.
- Aug 27, 2018 The 14th International Congress of Neuroimmunology, Brisbane, Australia. Host: Judith Greer, Ph.D.
Thematic: Targeting B cells in neuromyelitis optica spectrum disorders.
- Nov 24, 2017 The 10th Congress of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, (PACTRIMS), Ho Chi Minh City, Vietnam.
Thematic: Therapeutics and Health Care Policies for MS and NMOSD in Asia: Present Status and Road Blocks to Change - From China
- Oct 6, 2017 Stanford Neurosciences Institute. Host: Heng Zhao, M.D., Ph.D.
Thematic: Brain inflammation after stroke
- Sep 26, 2016 13th International Congress of Neuroimmunology, Jerusalem, Israel.
Thematic: Immunology of stroke: where are we heading next?
- Aug 06, 2016 MS Summer College, Kobe, Japan. Host: Kazuo Fujihara, M.D.
Thematic: Structural basis for cognitive dysfunction in patients with neuromyelitis optica spectrum Disorders.
- Apr 08, 2016 Neuroscience seminar at Massachusetts General Hospital, Boston, MA, USA. Host: Kimberly Kegel-Gleason, Ph.D.
Thematic: Stroke induced immune deficiency.
- Apr 07, 2016 Yale New Haven Hospital Neurology grand round. Host: Kevin N. Sheth, M.D.
Thematic: Immune modulations in ICH.
- Nov 19, 2015 The 8th Congress of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Seoul, Korea.
Thematic: Autologous mesenchymal stem cell in neuromyelitis optica spectrum disorder: a pilot study.
- Fri 11, 2014 NIH/NIAID immunology seminar series, Bethesda, MD, USA. Host: Eric O. Long, Ph.D.
Thematic: NK cells in autoimmunity.
- Sep 13, 2012 The 5th Congress of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, (PACTRIMS), Beijing, China.
Thematic: Demyelinating diseases in large Neurological center in China: a summary of five year management and follow up.
- Jun 25, 2011 The 11th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), Washington DC, USA. Host: Olivera Finn, Ph.D.
Thematic: Innate Immunity in Disease: Brain specificity of NK cells.
- Apr 10, 2010 The University of Arizona College of Medicine Host: Karen Hastings, MD, PhD.
Thematic: Multiple sclerosis therapies: an update.

Original articles

2024 BTKI NMO. J. Neuroinflammation 2022?

1. Li J*, Meng X*, **Shi FD***, Jing J*, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton DJ, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Xie X, Jin WN, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y. for the CHANCE-3 Investigators. Colchicine in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack (CHANCE-3): a multicenter, double-blind, randomised, placebo-controlled trial. **BMJ**. 2024, in press.
2. Jiang S, Li X, Li Y, Chang Z, Yuan M, Zhang Y, Zhu H, Xiu Y, Cong H, Yin L, Yu ZW, Fan J, He W, Shi K, Tian DC, Zhang J, Verkhratsky A, Jin WN, **Shi FD**. APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model. **Science Translational Medicine**. 2024;16(736):eadg5116.
3. Guo A, Zhang Z, Dong GH, Su L, Gao C, Zhang M, Shi X, Wang H, Zhang X, Lu DH, Fu Y, Jing J, **Shi FD**, Tian DC. Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System. **Ann Neurol**. 2024 Apr 25.
4. Jing J, Zhang Z, Su L, Gao C, Guo A, Liu X, Wang H, Zhang X, Liu Y, Comi G, Waubant E, **Shi FD**, Tian DC. Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI. **J Neurol Neurosurg Psychiatry**. 2024; jnnp-2023-332566.
5. Jia D, Zhang F, Li H, Shen Y, Jin Z, **Shi FD**, Zhang C. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis. **Aging Dis**. 2024;15(2):824-830.
6. Zhang C, Liu Y, Zhu H, Huang X, Guo C, Cheng S, Yuan M, Jiang Y, Meng X, Johnston SC, Wang Y, Jin WN, **Shi FD**. Potential Protein Signatures for Recurrence Prediction of Ischemic Stroke. **J Am Heart Assoc**. 2024;13(5):e032840.
7. Gao C, Su L, Li H, Song T, Liu Y, Duan Y, Shi FD. Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS. **Mult Scler Relat Disord**. 2024; 82:105406.
8. Wu S, Li Y, Zhao X, **Shi FD**, Chen J. Multiplex proteomics identifies inflammation-related plasma biomarkers for aging and cardio-metabolic disorders. **Clin Proteomics**. 2024;21(1):30.

2023

9. Li Z, Zhang C, Chang T, Zhang X, Yang H, Gao F, Feng J, Liu H, Chen S, Wang L, Yang C, Li H, Pan Y, Palace J, **Shi FD**; SCREAM Study Investigators. A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study. **Lancet RHPW**. 2023;38:100846.
10. Chen J, Zhao X, Zhang W, Zhang T, Wu S, Shao J, **Shi FD**. Reference intervals for plasma amyloid- β , total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment. **Alzheimer's Res Ther**. 2023;15(1):100.
11. Ren H, Pan Y, Wang D, Hao H, Han R, Qi C, Zhang W, He W, **Shi FD**, Liu Q. CD22 blockade modulates microglia activity to suppress neuroinflammation following intracerebral hemorrhage. **Pharmacol Res**. 2023;196:106912.
12. Yao N, Li Y, Han J, Wu S, Liu X, Wang Q, Li Z, **Shi FD**. Microglia-derived CCL20 deteriorates neurogenesis following intraventricular hemorrhage. **Exp Neurol**. 2023;370:114561.
13. Jia D, Zhang F, Li H, Shen Y, Jin Z, **Shi FD**, Zhang C. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis. **Aging Dis**. 2023.
14. Zhang Z, Li Y, Jiang S, **Shi FD**, Shi K, Jin WN. Targeting CCL5 signaling attenuates neuroinflammation after seizure. **CNS Neurosci Ther**. 2023;29(1):317-330.
15. Sun J, Xu S, Tian D, Duan Y, Xu X, Lv S, Cao G, **Shi FD**, Chard D, Barkhof F, Zhuo Z, Zhang X, Liu Y. Periventricular gradients in NAWM abnormalities differ in MS, NMOSD and MOGAD. **Mult Scler Relat Disord**. 2023;75:104732.
16. Wang Y, Li J, Johnston SC, Hankey GJ, Easton JD, Meng X, **Shi FD**, Wang Y, Zhao X, Li Z, Liu L, Gu H, Jiang Y, Wang A, Pan Y, Jing J, Niu S, Li H. Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial. **Int J Stroke**. 2023;18(7):873-878.

17. Zheng P, Xiu Y, Chen Z, Yuan M, Li Y, Wang N, Zhang B, Zhao X, Li M, Liu Q, **Shi FD**, Jin WN. Group 2 innate lymphoid cells resolve neuroinflammation following cerebral ischaemia. **Stroke Vasc Neurol**. 2023;svn-2022-001919.

2022

18. Shi K, Li H, Chang T, He W, Kong Y, Qi C, Li R, Huang H, Zhu Z, Zheng P, Ruan Z, Zhou J, **Shi FD**, Liu Q. Bone marrow hematopoiesis drives multiple sclerosis progression. **Cell**. 2022;185(13):2234-2247.e17.
19. Cheng N, Wang H, Zou M, Jin WN, **Shi FD**, Shi K. Brain-derived programmed death-ligand 1 mediates immunosuppression post intracerebral hemorrhage. **J Cereb Blood Flow Metab**. 2022;42(11):2048-2057.
20. Zhang Z, Jiang S, Shi K, Li Y, Jin WN, Liu Q, Zhao T, Cheng H, **Shi FD**. Visualizing Seizure Propagation in Freely-moving Mice via Miniature Two-photon Microscopy. **Neurosci Bull**. 2022;38(12):1593-1597.
21. Wu ST, Han JR, Yao N, Li YL, Zhang F, Shi Y, **Shi FD**, Li ZG. Activation of P2X4 receptor exacerbates acute brain injury after intracerebral hemorrhage. **CNS Neurosci Ther**. 2022;28(7):1008-1018.
22. Cai Y, Burton JM, **Shi FD**, Qiu W, Guan Y. Editorial: Advances in neuromyelitis optica spectrum disorders. **Front Neurol**. 2022;13:1005164.
23. Yao Y, Li X, Xu Y, Liang X, Yang L, **Shi FD**, Zhang X, Tian DC, Zhang X. The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON. **BMC Neurol**. 2022;22(1):323.
24. Guan Y, Zuo W, Jia K, Yu C, Liu F, Lv Z, Wang D, **Shi FD**, Wang X. Association of Red Blood Cell Distribution Width with Stroke Prognosis Among Patients with Small Artery Occlusion: A Hospital-Based Prospective Follow-Up Study. **Int J Gen Med**. 2022;15:7449-7457.
25. Zhuo Z, Zhang J, Duan Y, Qu L, Feng C, Huang X, Cheng D, Xu X, Sun T, Li Z, Guo X, Gong X, Wang Y, Jia W, Tian D, Zhang X, **Shi FD**, Haller S, Barkhof F, Ye C, Liu Y. Automated Classification of Intramedullary Spinal Cord Tumors and Inflammatory Demyelinating Lesions Using Deep Learning. **Radiol Artif Intell**. 2022;4(6):e210292.

2021

26. Jin WN, Shi K, He W, Sun JH, Van Kaer L, **Shi FD**, Liu Q. Neuroblast senescence in the aged brain ments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. **Nat Neurosci**. 2021;24(1):61-73.
27. Shi K, Zou M, Jia DM, Shi S, Yang X, Liu Q, Dong JF, Sheth KN, Wang X, **Shi FD**. tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke. **Circ Res**. 2021;128(1):62-75.
28. Li Z, Li Y, Han J, Zhu Z, Li M, Liu Q, Wang Y, **Shi FD**. Formyl peptide receptor 1 signaling potentiates inflammatory brain injury. **Sci Transl Med**. 2021;13(605):eabe9890.
29. Xu X, Wang C, Wu Y, Houck K, Hilton T, Zhou A, Wu X, Han C, Yang M, Yang W, **Shi FD**, Stolla M, Cruz MA, Li M, Zhang J, Dong JF. Conformation-dependent blockage of activated VWF improves outcomes of traumatic brain injury in mice. **Blood**. 2021;137(4):544-555.
30. Zheng P, Tian DC, Xiu Y, Wang Y, **Shi FD**. Incidence of Guillain-Barré syndrome (GBS) in China: A national population-based study. **Lancet RHPW**. 2021;18:100302.
31. Duan Y, Zhuo Z, Li H, Tian DC, Li Y, Yang L, Gao C, Zhang T, Zhang X, **Shi FD**, Barkhof F, Liu Y. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. **J Neurol Neurosurg Psychiatry**. 2021;92(7):709-716.
32. Feng Y, Li Y, Zhang Y, Zhang BH, Zhao H, Zhao X, **Shi FD**, Jin WN, Zhang XA. miR-1224 contributes to ischemic stroke-mediated natural killer cell dysfunction by targeting Sp1 signaling. **J Neuroinflammation**. 2021;18(1):133.
33. Zhang C, Zhang TX, Liu Y, Jia D, Zeng P, Du C, Yuan M, Liu Q, Wang Y, **Shi FD**. B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease. **Neurol Neuroimmunol Neuroinflamm**. 2021;8(6):e1070.
34. Xiu Y, Gu H, Li X, Li Z, Jin WN, Liu Q, **Shi FD**. Incidence and Mortality of Acute Disseminated Encephalomyelitis in China: A Nationwide Population-Based Study. **Neurosci Bull**. 2021;37(6):804-808.
35. Li H, Huang Z, Jia D, Xue H, Pan J, Zhang M, Shi K, **Shi FD**, Zhang C. Low-dose rituximab treatment for new-onset generalized myasthenia gravis. **J Neuroimmunol**. 2021;354:577528.
36. Du C, Zeng P, Han JR, Zhang TX, Jia D, **Shi FD**, Zhang C. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder. **Front Immunol**. 2021;12:660230.

37. Liu Y, Zhang H, Zhang TX, Yuan M, Du C, Zeng P, Huang Z, Jia D, Yang G, **Shi FD**, Zhang C. Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder. **Front Immunol**. 2021;12:703931.
38. Zhang TX, Chen JS, Du C, Zeng P, Zhang H, Wang X, Liu Y, Huang Z, Yuan M, Li YL, Jia D, **Shi FD**, Zhang C. Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. **Ther Adv Neurol Disord**. 2021;14:17562864211054952.
39. Zhuo Z, Duan Y, Tian D, Wang X, Gao C, Ding J, Zheng F, Zhang T, Zhang X, Barkhof F, **Shi FD**, Liu Y. Brain structural and functional alterations in MOG antibody disease. **Mult Scler**. 2021;27(9):1350-1363.
40. Li T, Li H, Li Y, Dong SA, Yi M, Zhang QX, Feng B, Yang L, **Shi FD**, Yang CS. Multi-Level Analyses of Genome-Wide Association Study to Reveal Significant Risk Genes and Pathways in Neuromyelitis Optica Spectrum Disorder. **Front Genet**. 2021;12:690537.
41. Li T, Zhang GQ, Li Y, Dong SA, Wang N, Yi M, Qi Y, Zhai H, Yang L, **Shi FD**, Yang CS. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. **J Clin Neurosci**. 2021;85:6-12.

2020

42. Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, **Shi FD**. Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study. **Lancet RHWP**. 2020;2:100021.
43. Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, **Shi FD**; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. **Lancet Neurol**. 2020;19(5):391-401.
44. Tian DC, Zhang C, Yuan M, Yang X, Gu H, Li Z, Wang Y, **Shi FD**. Incidence of multiple sclerosis in China: A nationwide hospital-based study. **Lancet RHWP**. 2020;1:100010.
45. Chen J, Tian DC, Zhang C, Li Z, Zhai Y, Xiu Y, Gu H, Li H, Wang Y, **Shi FD**. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. **Lancet RHWP**. 2020;5:100063.
46. Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, Lau AY, Guo J, Zhang MN, Zhang X, Yang CS, Chen J, Zheng P, Liu Q, Zhang C, **Shi FD**. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. **Neurol Neuroimmunol Neuroinflamm**. 2020;7(5):e787.
47. Miyares LC, Falcone GJ, Leasure A, Adeoye O, **Shi FD**, Kittner SJ, Langefeld C, Vagal A, Sheth KN, Woo D. Race/ethnicity influences outcomes in young adults with supratentorial intracerebral hemorrhage. **Neurology**. 2020;94(12):e1271-e1280.
48. Li YJ, Shi SX, Liu Q, **Shi FD**, Gonzales RJ. Targeted role for sphingosine-1-phosphate receptor 1 in cerebrovascular integrity and inflammation during acute ischemic stroke. **Neurosci Lett**. 2020;735:135160.
49. Zhao Z, Zhou Y, Hilton T, Li F, Han C, Liu L, Yuan H, Li Y, Xu X, Wu X, Zhang F, Thiagara P, Cap A, **Shi FD**, Zhang J, Dong JF. Extracellular mitochondria released from traumatized brains induced platelet procoagulant activity. **Haematologica**. 2020 ;105(1):209-217.
50. Liu A, **Shi FD**, Cohen IR, Castaldo G, Matarese G, Quintana FJ, La Cava A. DNA vaccine encoding heat shock protein 90 protects from murine lupus. **Arthritis Res Ther**. 2020;22(1):152.
51. Zhang C, Bu B, Yang H, Wang L, Liu W, Duan RS, Zhang M, Zeng P, Du C, Yang L, **Shi FD**. Immunotherapy choice and maintenance for generalized myasthenia gravis in China. **CNS Neurosci Ther**. 2020;26(12):1241-1254.
52. Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, Jia D, Xu W, Song T, **Shi FD**, Zhang X. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). **Mult Scler Relat Disord**. 2020;44:102325.
53. Tian DC, Xiu Y, Wang X, Shi K, Fan M, Li T, Li H, Su L, Ma Y, Xu W, Song T, Liu Y, **Shi FD**, Zhang X. Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders. **Front Neurol**. 2020;11:872.
54. Liu A, Ferretti C, **Shi FD**, Cohen IR, Quintana FJ, La Cava A. DNA Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (NZB × NZW)F1 Mice. **Arthritis Rheumatol**. 2020;72(6):997-1002.
55. An J, Yin JJ, He Y, Sui RX, Miao Q, Wang Q, Yu JZ, Yu JW, **Shi FD**, Ma CG, Xiao BG. Temporal and Spatial Dynamics of Astroglial Reaction and Immune Response in Cuprizone-Induced Demyelination. **Neurotox Res**. 2020;37(3):587-601.

56. Zhang N, Sun J, Wang Q, Qin W, Zhang X, Qi Y, Yang L, **Shi FD**, Yu C. Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. **Mult Scler Relat Disord**. 2020;41:102035.
57. Zheng H, Yang Y, Chen H, Li C, Chen Y, **Shi FD**, Yang L, Cui X, Lu Z, Liang Y, Cui S, Xu A, Wu Y, Sun Y, Wang Y. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China. **Stroke Vasc Neurol**. 2020;5(3):285-290.

2019

58. Guo X, Zhu J, Zhang N, Zhang L, Qi Y, Cai H, Zhang X, Sun J, Wang Q, Yang L, **Shi FD**, Yu C. Altered neurovascular coupling in neuromyelitis optica. **Hum Brain Mapp**. 2019;40(3):976-986.
59. Shi K, Zhang J, Dong JF, **Shi FD**. Dissemination of brain inflammation in traumatic brain injury. **Cell Mol Immunol**. 2019;16(6):523-530.
60. Liu Q, **Shi FD**. Enhancing natural killer cells is beneficial in multiple sclerosis - No. **Mult Scler**. 2019;25(4):512-513.
61. Yang CS, Guo A, Li Y, Shi K, **Shi FD**, Li M. D1-3-n-butylphthalide Reduces Neurovascular Inflammation and Ischemic Brain Injury in Mice. **Aging Dis**. 2019;10(5):964-976.
62. Zhao H, Feng Y, Wei C, Li Y, Ma H, Wang X, Cui Z, Jin WN, **Shi FD**. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. **Neuroscience**. 2019;416:198-206.
63. Leasure AC, Qureshi AI, Murthy SB, Kamel H, Goldstein JN, Walsh KB, Woo D, **Shi FD**, Huttner HB, Ziai WC, Hanley DF, Matouk CC, Sansing LH, Falcone GJ, Sheth KN. Intensive Blood Pressure Reduction and Perihematomal Edema Expansion in Deep Intracerebral Hemorrhage. **Stroke**. 2019;50(8):2016-2022.
64. Liu Q, Li M, Whiteaker P, **Shi FD**, Morley BJ, Lukas RJ. Attenuation in Nicotinic Acetylcholine Receptor $\alpha 9$ and $\alpha 10$ Subunit Double Knock-Out Mice of Experimental Autoimmune Encephalomyelitis. **Biomolecules**. 2019;9(12):827.
65. Yang CS, Zhang QX, Deng Y, Zhou BJ, Zhang LJ, Li LM, Qi Y, Wang J, Yang L, **Shi FD**. Increased serum IL-36 β and IL-36 γ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity. **BMC Neurol**. 2019;19(1):185.
66. Yang C, Yang Y, Ma L, Zhang GX, **Shi FD**, Yan Y, Chang G. Study of the cytological features of bone marrow mesenchymal stem cells from patients with neuromyelitis optica. **Int J Mol Med**. 2019;43(3):1395-1405.
67. Zhang F, Zhao Q, Jiang Y, Liu N, Liu Q, **Shi FD**, Hao J, Xu Y, Lo EH, Wang X. mented Brain Infiltration and Activation of Leukocytes After Cerebral Ischemia in Type 2 Diabetic Mice. **Front Immunol**. 2019;10:2392.
68. Li H, Zhou X, Li Y, Ma X, Gonzales RJ, Qiu S, **Shi FD**, Liu Q. The selective sphingosine 1-phosphate receptor 1 modulator RP101075 improves microvascular circulation after cerebrovascular thrombosis. **FASEB J**. 2019;33(10):10935-10941.
69. Zeng S, Zhang MY, Wang XJ, Hu ZM, Li JC, Li N, Wang JL, Liang F, Yang Q, Liu Q, Fang L, Hao JW, **Shi FD**, Ding XB, Teng JF, Yin XM, Jiang H, Liao WP, Liu JY, Wang K, Xia K, Tang BS. Long-read sequencing identified intronic repeat expansions in SAMD12 from Chinese pedigrees affected with familial cortical myoclonic tremor with epilepsy. **J Med Genet**. 2019;56(4):265-270.

2018

70. Wu Y, Liu W, Zhou Y, Hilton T, Zhao Z, Liu W, Wang M, Yeon J, Houck K, Thiagara P, Zhang F, **Shi FD**, Wu X, Li M, Dong JF, Zhang J. von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury. **Blood**. 2018;132(10):1075-1084.
71. Zhou Y, Cai W, Zhao Z, Hilton T, Wang M, Yeon J, Liu W, Zhang F, **Shi FD**, Wu X, Thiagara P, Li M, Zhang J, Dong JF. Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice. **Blood**. 2018;131(5):563-572.
72. Zhang CJ, Jiang M, Zhou H, Liu W, Wang C, Kang Z, Han B, Zhang Q, Chen X, Xiao J, Fisher A, Kaiser WJ, Murayama MA, Iwakura Y, Gao J, Carman J, Dongre A, Dubyak G, Abbott DW, **Shi FD**, Ransohoff RM, Li X. TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation. **J Clin Invest**. 2018;128(12):5399-5412.
73. Jin WN, Gonzales R, Feng Y, Wood K, Chai Z, Dong JF, La Cava A, **Shi FD**, Liu Q. Brain Ischemia Induces Diversified

Neuroantigen-Specific T-Cell Responses That Exacerbate Brain Injury. **Stroke**. 2018;49(6):1471-1478.

74. Zhang C, **Shi FD**. Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. **JAMA Neurol**. 2018;75(1):129-130.
75. Li LM, Zhang C, Zhang LJ, Guo HY, Yang CS, Zhang R, Li YJ, **Shi FD**, Yang L. Relapse of neuromyelitis optica associated with oral progestin. **J Neurol Neurosurg Psychiatry**. 2018;89(7):788-789.
76. Li Z, Li M, Wood K, Hettwer S, Muley SA, **Shi FD**, Liu Q, Ladha SS. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis. **Muscle Nerve**. 2018;57(5):814-820.
77. Li Z, Han J, Ren H, Ma CG, **Shi FD**, Liu Q, Li M. Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice. **Front Immunol**. 2018;9:523.
78. Liu Y, Jiang X, Butzkueven H, Duan Y, Huang J, Ren Z, Dong H, **Shi FD**, Barkhof F, Li K, Wang J. Multimodal characterization of gray matter alterations in neuromyelitis optica. **Mult Scler**. 2018;24(10):1308-1316.
79. Zhang F, Yan C, Wei C, Yao Y, Ma X, Gong Z, Liu S, Zang D, Chen J, **Shi FD**, Hao J. Vinpocetine Inhibits NF- κ B-Dependent Inflammation in Acute Ischemic Stroke Patients. **Transl Stroke Res**. 2018;9(2):174-184.
80. Yang X, Ren H, Wood K, Li M, Qiu S, **Shi FD**, Ma C, Liu Q. Depletion of microglia ments the dopaminergic neurotoxicity of MPTP. **FASEB J**. 2018;32(6):3336-3345.
81. Murphy MP, Kuramatsu JB, Leasure A, Falcone GJ, Kamel H, Sansing LH, Kourkoulis C, Schwab K, Elm JJ, Gurol ME, Tran H, Greenberg SM, Viswanathan A, Anderson CD, Schwab S, Rosand J, **Shi FD**, Kittner SJ, Testai FD, Woo D, Langefeld CD, James ML, Koch S, Huttner HB, Biffi A, Sheth KN. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. **Stroke**. 2018;49(11):2652-2658.
82. Li T, Zhang LJ, Zhang QX, Yang CS, Zhang C, Li YJ, **Shi FD**, Yang L. Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. **J Neuroimmunol**. 2018;316:107-111.
83. Zhang CJ, Wang C, Jiang M, Gu C, Xiao J, Chen X, tin BN, Tang F, Yamamoto E, Xian Y, Wang H, Li F, Sartor RB, Smith H, Husni ME, **Shi FD**, Gao J, Carman J, Dongre A, McKarns SC, Coppieters K, Jørgensen TN, Leonard WJ, Li X. Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. **Nat Commun**. 2018;9(1):2745.
84. Zhang J, Shi K, Li Z, Li M, Han Y, Wang L, Zhang Z, Yu C, Zhang F, Song L, Dong JF, La Cava A, Sheth KN, **Shi FD**. Organ- and cell-specific immune responses are associated with the outcomes of intracerebral hemorrhage. **FASEB J**. 2018;32(1):220-229.
85. Yang CS, Zhang QX, Chang SH, Zhang LJ, Li LM, Qi Y, Wang J, Sun ZH, Zhangning N, Yang L, **Shi FD**. Neuromyelitis optica spectrum disorders with and without connective tissue disorders. **BMC Neurol**. 2018;18(1):177.
86. Tian DC, Su L, Fan M, Yang J, Zhang R, Wen P, Han Y, Yu C, Zhang C, Ren H, Shi K, Zhu Z, Dong Y, Liu Y, **Shi FD**. Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). **Mult Scler**. 2018;24(12):1585-1593.
87. Luo H, Wood K, **Shi FD**, Gao F, Chang Y. Suramin is a el competitive antagonist selective to $\alpha 1\beta 2\gamma 2$ GABAA over $\rho 1$ GABAC receptors. **Neuropharmacology**. 2018;141:148-157.
88. Jin WN, Ducruet AF, Liu Q, Shi SX, Waters M, Zou M, Sheth KN, Gonzales R, **Shi FD**. Activation of JAK/STAT3 restores NK-cell function and improves immune defense after brain ischemia. **FASEB J**. 2018;32(5):2757-2767.
89. Zhang X, Guo X, Zhang N, Cai H, Sun J, Wang Q, Qi Y, Zhang L, Yang L, **Shi FD**, Yu C. Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability. **Front Neurol**. 2018;9:305.
90. Yang CS, Zhang LJ, Sun ZH, Yang L, **Shi FD**. Acute prevertebral abscess secondary to intradiscal oxygen-ozone chemonucleolysis for treatment of a cervical disc herniation. **J Int Med Res**. 2018;46(6):2461-2465.
91. Liu Y, Duan Y, Huang J, Ren Z, Liu Z, Dong H, Weiler F, Hahn HK, **Shi FD**, Butzkueven H, Barkhof F, Li K. Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. **Eur Radiol**. 2018;28(1):96-103.
92. Tian DC, Shi K, Zhu Z, Yao J, Yang X, Su L, Zhang S, Zhang M, Gonzales RJ, Liu Q, Huang D, Waters MF, Sheth KN, Ducruet AF, Fu Y, Lou M, **Shi FD**. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. **Ann Neurol**. 2018;84(5):717-728.

93. Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, Zhang C, Gonzales RJ, Sheth KN, La Cava A, **Shi FD**. Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. **Immunity**. 2017;46(3):474-487.
94. Jiang W, Li D, Han R, Zhang C, Jin WN, Wood K, Liu Q, **Shi FD**, Hao J. Acetylcholine-producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes/macrophages. **Proc Natl Acad Sci U S A**. 2017;114(30):E6202-E6211.
95. Li M, Li Z, Yao Y, Jin WN, Wood K, Liu Q, **Shi FD**, Hao J. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. **Proc Natl Acad Sci U S A**. 2017;114(3):E396-E405.
96. Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, **Shi FD**. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. **JAMA Neurol**. 2017;74(8):1010-1012.
97. Li M, Ren H, Sheth KN, **Shi FD**, Liu Q. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. **FASEB J**. 2017;31(8):3278-3287.
98. Sreekrishnan A, Leasure AC, **Shi FD**, Hwang DY, Schindler JL, Petersen NH, Gilmore EJ, Kamel H, Sansing LH, Greer DM, Sheth KN. Functional Improvement Among Intracerebral Hemorrhage (ICH) Survivors up to 12 Months Post-injury. **Neurocrit Care**. 2017;27(3):326-333.
99. Wang Z, Guo W, Liu Y, Gong Y, Ding X, Shi K, Thome R, Zhang GX, **Shi FD**, Yan Y. Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. **Brain Behav Immun**. 2017;65:173-182.
100. Grunwald Z, Beslow LA, Urdy S, Vashkevich A, Ayres A, Greenberg SM, Goldstein JN, Leasure A, **Shi FD**, Kahle KT, Battey TW, Sid JM, Rosand J, Kimberly WT, Sheth KN. Perihematomal Edema Expansion Rates and Patient Outcomes in Deep and Lobar Intracerebral Hemorrhage. **Neurocrit Care**. 2017;26(2):205-212.
101. Li M, Li Z, Ren H, Jin WN, Wood K, Liu Q, Sheth KN, **Shi FD**. Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. **J Cereb Blood Flow Metab**. 2017;37(7):2383-2395.
102. Feng Y, Liao S, Wei C, Jia D, Wood K, Liu Q, Wang X, **Shi FD**, Jin WN. Infiltration and persistence of lymphocytes during late-stage cerebral ischemia in middle cerebral artery occlusion and photothrombotic stroke models. **J Neuroinflammation**. 2017;14(1):248.
103. Zhang S, Zhou Y, Zhang R, Zhang M, Campbell B, Lin L, **Shi FD**, Lou M. Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial. **Int J Stroke**. 2017;12(8):906-909.
104. Fan M, Fu Y, Su L, Shen Y, Wood K, Yang L, Liu Y, **Shi FD**. Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. **Mult Scler Relat Disord**. 2017;13:58-66.
105. Liu Q, Whiteaker P, Morley BJ, **Shi FD**, Lukas RJ. Distinctive Roles for $\alpha 7^{*}$ - and $\alpha 9^{*}$ -Nicotinic Acetylcholine Receptors in Inflammatory and Autoimmune Responses in the Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. **Front Cell Neurosci**. 2017;11:287.

106. Wu W, Cui L, Fu Y, Tian Q, Liu L, Zhang X, Du N, Chen Y, Qiu Z, Song Y, **Shi FD**, Xue R. Sleep and Cognitive Abnormalities in Acute Minor Thalamic Infarction. **Neurosci Bull**. 2016;32(4):341-8.
107. Yao Y, Miao W, Liu Z, Han W, Shi K, Shen Y, Li H, Liu Q, Fu Y, Huang D, **Shi FD**. Dimethyl Fuate and Monomethyl Fuate Promote Post-Ischemic Recovery in Mice. **Transl Stroke Res**. 2016;7(6):535-547.
108. Sun N, Shen Y, Han W, Shi K, Wood K, Fu Y, Hao J, Liu Q, Sheth KN, Huang D, **Shi FD**. Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage. **Stroke**. 2016;47(7):1899-906.
109. Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett JL, Vollmer TL, **Shi FD**. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. **Sci China Life Sci**. 2016;59(12):1270-1281.
110. Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, **Shi FD**. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. **Nat Neurosci**. 2016;19(2):243-52.

111. Qi Y, Jia K, Zhang DQ, Li T, Li LM, Zhang LJ, Wang J, Gao CL, Sun LS, **Shi FD**, Yang L. Increased resistin levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica. **Clin Chim Acta**. 2016;456:176-179.
 112. Su L, Han Y, Xue R, Wood K, **Shi FD**, Liu Y, Fu Y. Thalamic Atrophy Contributes to Low Slow Wave Sleep in Neuromyelitis Optica Spectrum Disorder. **Aging Dis**. 2016;7(6):691-696.
 113. Shi K, Wang Z, Liu Y, Gong Y, Fu Y, Li S, Wood K, Hao J, Zhang GX, **Shi FD**, Yan Y. CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders. **J Immunol**. 2016;197(9):3471-3480.
 114. Jin WN, Yang X, Li Z, Li M, Shi SX, Wood K, Liu Q, Fu Y, Han W, Xu Y, **Shi FD**, Liu Q. Non-invasive tracking of CD4+ T cells with a paramagnetic and fluorescent nanoparticle in brain ischemia. **J Cereb Blood Flow Metab**. 2016;36(8):1464-76.
 115. Shu N, Duan Y, Xia M, Schoonheim MM, Huang J, Ren Z, Sun Z, Ye J, Dong H, **Shi FD**, Barkhof F, Li K, Liu Y. Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis. **Sci Rep**. 2016;6:29383.
 116. Zhang CJ, Gong Y, Zhu W, Qi Y, Yang CS, Fu Y, Chang G, Li Y, Shi S, Wood K, Ladha S, **Shi FD**, Liu Q, Yan Y. Mentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis. **J Immunol**. 2016;197(7):2610-7.
 117. Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N, Yu C, Su L, Zhang R, Shen Y, Lin S, Liu Q, Shao Z, Han Z, **Shi FD**. Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study. **CNS Neurosci Ther**. 2016;22(8):677-85.
 118. Li D, Wang C, Yao Y, Chen L, Liu G, Zhang R, Liu Q, **Shi FD**, Hao J. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. **FASEB J**. 2016;30(10):3388-3399.
- 2015**
119. **Shi FD**. Neuroinflammation. **Neurosci Bull**. 2015;31(6):714-6.
 120. Zhang LJ, Zhao N, Fu Y, Zhang DQ, Wang J, Qin W, Zhang N, Wood K, Liu Y, Yu C, **Shi FD**, Yang L. Olfactory dysfunction in neuromyelitis optica spectrum disorders. **J Neurol**. 2015;262(8):1890-8.
 121. Song Y, Pan L, Fu Y, Sun N, Li YJ, Cai H, Su L, Shen Y, Cui L, **Shi FD**. Sleep abnormality in neuromyelitis optica spectrum disorder. **Neurol Neuroimmunol Neuroinflamm**. 2015;2(3):e94.
 122. Liu Y, Liang P, Duan Y, Huang J, Ren Z, Jia X, Dong H, Ye J, **Shi FD**, Butzkueven H, Li K. Altered thalamic functional connectivity in multiple sclerosis. **Eur J Radiol**. 2015;84(4):703-8.
 123. Wang J, Li X, Zhang DQ, Yang CS, Qi Y, Li MS, **Shi FD**, Yang L. Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis. **J Neuroimmunol**. 2015;278:26-9.
 124. Liu Y, Fu Y, Schoonheim MM, Zhang N, Fan M, Su L, Shen Y, Yan Y, Yang L, Wang Q, Zhang N, Yu C, Barkhof F, **Shi FD**. Structural MRI substrates of cognitive impairment in neuromyelitis optica. **Neurology**. 2015;85(17):1491-9.
 125. Li YJ, Chang GQ, Liu Y, Gong Y, Yang C, Wood K, **Shi FD**, Fu Y, Yan Y. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. **Neurosci Bull**. 2015;31(6):755-62.
 126. Li YJ, Zhang F, Qi Y, Chang GQ, Fu Y, Su L, Shen Y, Sun N, Borazanci A, Yang C, **Shi FD**, Yan Y. Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. **J Neuroimmunol**. 2015;278:239-46.
 127. Yue X, Tian L, Fan X, Xu G, **Shi FD**, Liu X. Chromosome 9p21.3 Variants Are Associated with Cerebral Infarction in Chinese Population. **J Mol Neurosci**. 2015;56(3):546-52.
 128. Liu Y, Duan Y, Huang J, Ren Z, Ye J, Dong H, **Shi FD**, Barkhof F, Vrenken H, Wattjes MP, Wang J, Li K. Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. **Radiology**. 2015;277(3):784-92.
 129. Liu Y, Wang J, Daams M, Weiler F, Hahn HK, Duan Y, Huang J, Ren Z, Ye J, Dong H, Vrenken H, Wattjes MP, **Shi FD**, Li K, Barkhof F. Differential patterns of spinal cord and brain atrophy in NMO and MS. **Neurology**. 2015;84(14):1465-72.
 130. Pan J, Zhao P, Cai H, Su L, Wood K, **Shi FD**, Fu Y. Hypoxemia, Sleep Disturbances, and Depression Correlated with

Fatigue in Neuromyelitis Optica Spectrum Disorder. **CNS Neurosci Ther.** 2015;21(7):599-606.

131. Zhang C, Xie B, **Shi FD**, Hao J. Neurological picture. Multiple intracranial arteritis and hypothyroidism secondary to Streptococcus anginosus infection. **J Neurol Neurosurg Psychiatry.** 2015;86(9):1044-5.
132. Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, **Shi FD**. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial. **Circulation.** 2015;132(12):1104-1112.
133. Zhang N, Wei C, Du H, **Shi FD**, Cheng Y. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. **Dement Geriatr Cogn Disord.** 2015;40(1-2):85-93.
- 2014**
134. Liu Q, Tang Z, Gan Y, Wu W, Kousari A, La Cava A, **Shi FD**. Genetic deficiency of $\beta 2$ -containing nicotinic receptors attenuates brain injury in ischemic stroke. **Neuroscience.** 2014;256:170-7.
135. Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, Wang Y, Chen J, La Cava A, Poursine-Laurent J, Yokoyama W, **Shi FD**. Ischemic neurons recruit natural killer cells that accelerate brain infarction. **Proc Natl Acad Sci U S A.** 2014;111(7):2704-9.
136. Kong XD, Bai S, Chen X, Wei HJ, Jin WN, Li MS, Yan Y, **Shi FD**. Alterations of natural killer cells in traumatic brain injury. **Neurosci Bull.** 2014 ;30(6):903-912.
137. Liu Q, Xin W, He P, Turner D, Yin J, Gan Y, **Shi FD**, Wu J. Interleukin-17 inhibits adult hippocampal neurogenesis. **Sci Rep.** 2014;4:7554.
138. Ailloy G, Lourenço EV, **Shi FD**, La Cava A. IL-17 promotes murine lupus. **J Immunol.** 2014;193(2):540-3.
139. Liu Y, Liu A, Iikuni N, Xu H, **Shi FD**, La Cava A. Regulatory CD4+ T cells promote B cell anergy in murine lupus. **J Immunol.** 2014;192(9):4069-73.
140. Zhang CJ, Zhai H, Yan Y, Hao J, Li MS, Jin WN, Su N, Vollmer TL, **Shi FD**. Glatiramer acetate ameliorates experimental autoimmune neuritis. **Immunol Cell Biol.** 2014;92(2):164-9.
141. Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, **Shi FD**, Zhou QH. NK cell phenotypic modulation in lung cancer environment. **PLoS One.** 2014;9(10):e109976.
142. Wang J, Li X, Zhang DQ, Yang CS, Qi Y, Li MS, **Shi FD**, Yang L. Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis. **J Neuroimmunol.** 2015;278:26-9.
143. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, **Shi FD**. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. **JAMA Neurol.** 2014;71(9):1092-101.
144. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, **Shi FD**. Impact of an immune modulator fingolimod on acute ischemic stroke. **Proc Natl Acad Sci U S A.** 2014;111(51):18315-20.
145. Tang Z, Gan Y, Liu Q, Yin JX, Liu Q, Shi J, **Shi FD**. CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. **J Neuroinflammation.** 2014;11:26.
146. Zhang J, Meng L, Qin W, Liu N, **Shi FD**, Yu C. Structural damage and functional reorganization in ipsilesional m1 in well-recovered patients with subcortical stroke. **Stroke.** 2014;45(3):788-93.
147. Liu Y, Xie T, He Y, Duan Y, Huang J, Ren Z, Gong G, Wang J, Ye J, Dong H, Butzkueven H, **Shi FD**, Shu N, Li K. Cortical thinning correlates with cognitive change in multiple sclerosis but not in neuromyelitis optica. **Eur Radiol.** 2014;24(9):2334-43.
148. Yang CS, Zhang DQ, Wang JH, Jin WN, Li MS, Liu J, Zhang CJ, Li T, **Shi FD**, Yang L. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China. **CNS Neurosci Ther.** 2014;20(1):32-9.
149. Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bompreszi R, **Shi FD**. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. **Muscle Nerve.** 2014;49(4):487-94.
150. Li YJ, Zhang F, Qi Y, Chang GQ, Fu Y, Su L, Shen Y, Sun N, Borazanci A, Yang C, **Shi FD**, Yan Y. Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. **J Neuroimmunol.** 2015;278:239-46.
151. Su N, Shi SX, Zhu X, Borazanci A, **Shi FD**, Gan Y. Interleukin-7 expression and its effect on natural killer cells in

patients with multiple sclerosis. **J Neuroimmunol.** 2014;276(1-2):180-6.

2013

152. Ailyo G, Iikuni N, **Shi FD**, Liu A, Matarese G, La Cava A. Leptin promotes lupus T-cell autoimmunity. **Clin Immunol.** 2013;149(3):530-3.
153. Bell JC, Liu Q, Gan Y, Liu Q, Liu Y, **Shi FD**, Turner GH. Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI. **J Neuroimmunol.** 2013;264(1-2):35-40.
154. Yu Y, Liu Y, **Shi FD**, Zou H, Matarese G, La Cava A. Cutting edge: Leptin-induced ROR γ t expression in CD4⁺ T cells promotes Th17 responses in systemic lupus erythematosus. **J Immunol.** 2013;190(7):3054-8.
155. Sid AR, Gan Y, St-Pierre S, Kousari A, Patel V, Whiteaker P, Morley BJ, Lukas RJ, **Shi FD**. Differential modulation of EAE by α 9*- and β 2*-nicotinic acetylcholine receptors. **Immunol Cell Biol.** 2013;91(3):195-200.
156. Hao J, **Shi FD**, Abdelwahab M, Shi SX, Sid A, Whiteaker P, Lukas R, Zhou Q. Nicotinic receptor β 2 determines NK cell-dependent metastasis in a murine model of metastatic lung cancer. **PLoS One.** 2013;8(2):e57495.
157. Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH, Yu C, **Shi FD**. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. **Neurology.** 2013;81(8):710-3.
158. Bell J, Zhao Q, Wang YJ, Liu QW, Turner G, **Shi FD**. Imaging optic nerve and spinal cord lesions in myelin antigen TCR transgenic mice with high-field rodent MRI. **Multiple Sclerosis Journal.** 2013; 19 (5), 692-692.
159. Shi XY, Ghanian S, Kousari A, Yang CS, **Shi FD**, Gan Y. Deficiency of natural killer cells in patients with multiple sclerosis is associated with aberrance of interleukin-7S. **Multiple Sclerosis Journal.** 2013; 19 (5), 675-675.
160. Yan Y, Ding X, Rostami A, **Shi FD**, Zhang GX. IFN-gamma signaling in astrocytes and microglia has opposite effects in CNS autoimmunity. **Multiple Sclerosis Journal.** 2013; 19 (5), 691-691.
161. Sun C, Wang Q, Zhou H, Yu S, Simard AR, Kang C, Li Y, Kong Y, An T, Wen Y, **Shi FD**, Hao J. Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo. **Neurosci Bull.** 2013;29(1):83-93.

162.

2012

163. Kim DY, Hao J, Liu R, Turner G, **Shi FD**, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. **PLoS One.** 2012;7(5):e35476.
164. Yu Y, Liu Y, **Shi FD**, Zou H, Hahn BH, La Cava A. Tolerance induced by anti-DNA Ig peptide in (NZB \times NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. **Clin Immunol.** 2012;142(3):291-5.
165. Shi QG, Wang ZH, Ma XW, Zhang DQ, Yang CS, **Shi FD**, Yang L. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis. **Neurosci Bull.** 2012;28(5):469-74.
166. Gan Y, Liu R, Wu W, Bompreszi R, **Shi FD**. Antibody to α 4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. **J Neuroimmunol.** 2012;247(1-2):9-15.
167. Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, **Shi FD**, Whitacre CC, Trgovcich J, Bai XF. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to finally enhanced development of autoimmune encephalomyelitis. **J Immunol.** 2012;188(7):3099-106.
168. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hooper JK, Eschbacher J, Liu R, **Shi FD**, Abdelwahab MG, Scheck AC, Preul MC. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival. **Cancer Manag Res.** 2012;4:325-34.
169. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hooper JK, Eschbacher J, Liu R, **Shi FD**, Abdelwahab MG, Scheck AC, Preul MC. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain. **Cancer Manag Res.** 2012;4:309-23.
170. Wu W, Shi S, Ljunggren HG, Cava AL, Van Kaer L, **Shi FD**, Liu R. NK cells inhibit T-bet-deficient, autoreactive Th17 cells. **Scand J Immunol.** 2012;76(6):559-66.

171. **Shi FD**, Jia JP. Neurology and neurologic practice in China. **Neurology**. 2011;77(22):1986-92.
172. Tybl E, **Shi FD**, Kessler SM, Tierling S, Walter J, Bohle RM, Wieland S, Zhang J, Tan EM, Kierner AK. Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype. **J Hepatol**. 2011;54(5):994-1001.
173. Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, **Shi FD**. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. **Ann Neurol**. 2011;69(4):721-34.
174. Hao J, Sid AR, Turner GH, Wu J, Whiteaker P, Lukas RJ, **Shi FD**. Attenuation of CNS inflammatory responses by nicotine involves $\alpha 7$ and non- $\alpha 7$ nicotinic receptors. **Exp Neurol**. 2011;227(1):110-9.
175. Feng ZH, Hao J, Ye L, Dayao C, Yan N, Yan Y, Chu L, **Shi FD**. Overexpression of μ -calpain in the anterior temporal neocortex of patients with intractable epilepsy correlates with clinicopathological characteristics. **Seizure**. 2011;20(5):395-401.

2010

176. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, **Shi FD**. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. **Eur J Immunol**. 2010;40(6):1577-89.
177. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, **Shi FD**. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. **J Exp Med**. 2010;207(9):1907-21.
178. Kala M, Rhodes SN, Piao WH, **Shi FD**, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. **Exp Neurol**. 2010;221(1):136-45.
179. Yin JX, Tu JL, Lin HJ, **Shi FD**, Liu RL, Zhao CB, Coons SW, Kuniyoshi S, Shi J. Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model. **PLoS One**. 2010;5(8):e12400.

2009

180. **Shi FD**, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. **J Immunol**. 2009;182(3):1730-9.
181. Liu R, Hao J, Dayao CS, **Shi FD**, Campagnolo DI. T-bet deficiency reases susceptibility to experimental myasthenia gravis. **Exp Neurol**. 2009;220(2):366-73.
182. Lourenço EV, Procaccini C, Ferrera F, Ikuni N, Singh RP, Filaci G, Matarese G, **Shi FD**, Brahn E, Hahn BH, La Cava A. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. **J Immunol**. 2009;182(12):7415-21.
183. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, **Shi FD**, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? **Mult Scler**. 2009;15(8):959-64.

2008

184. Liu R, Bai Y, Vollmer TL, Bai XF, Jee Y, Tang YY, Campagnolo DI, Collins M, Young DA, La Cava A, **Shi FD**. IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. **Exp Neurol**. 2008;211(1):14-24.
185. Bai Y, Liu R, Huang D, La Cava A, Tang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, **Shi FD**. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. **Eur J Immunol**. 2008;38(7):1877-88.
186. Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai XF, La Cava A, **Shi FD**. IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. **Scand J Immunol**. 2008;67(1):37-46.
187. Zhao CB, Coons SW, Cui M, **Shi FD**, Vollmer TL, Ma CY, Kuniyoshi SM, Shi J. A new EAE model of brain

demyelination induced by intracerebroventricular pertussis toxin. **Biochem Biophys Res Commun.** 2008;370(1):16-21.

2007

- 188.Schwartz EI, Smile LB, Price MA, Osredkar T, Baker RA, Ghosh S, **Shi FD**, Vollmer TL, Lencinas A, Stearns DM, Gorospe M, Kruman II. Cell cycle activation in postmitotic neurons is essential for DNA repair. **Cell Cycle.** 2007;6(3):318-29.
- 189.Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebh R, Campagnolo DI, **Shi FD**, Vollmer TL. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. **Clin Immunol.** 2007;125(1):34-42.
- 190.Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, **Shi FD**. Therapeutic effect of anthracene-based anticancer agent etnonafide in an animal model of multiple sclerosis. **J Immunol.** 2007;179(11):7415-23.
- 191.Liu JQ, Carl JW Jr, Joshi PS, RayChaudhury A, Pu XA, **Shi FD**, Bai XF. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. **J Immunol.** 2007;178(10):6227-35.
- 192.Ferrera F, Hahn BH, Rizzi M, Anderson M, Fitzgerald J, Millo E, Indiveri F, **Shi FD**, Filaci G, La Cava A. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. **Arthritis Rheum.** 2007;56(6):1945-53.
- 193.Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, **Shi FD**, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. **Arch Neurol.** 2007;64(10):1407-15.

2006

- 194.Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, **Shi FD**. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. **J Immunol.** 2006;176(9):5247-54.
- 195.Huang D, **Shi FD**, g S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. **FASEB J.** 2006;20(7):896-905.
- 196.Bakhiet M, Yu LY, Ozenci V, Khan A, **Shi FD**. Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen. **Clin Exp Immunol.** 2006;144(2):290-8.
- 197.Looi K, Megliorino R, **Shi FD**, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. **Oncol Rep.** 2006;16(5):1105-10.
- 198.Jee Y, Liu R, Bai XF, Campagnolo DI, **Shi FD**, Vollmer TL. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? **Int Immunol.** 2006;18(4):537-44.
- 199.Huang D, **Shi FD**, g S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. **FASEB J.** 2006;20(7):896-905.
- 200.Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, **Shi FD**, Ljunggren HG, Bai XF. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. **J Leukoc Biol.** 2006;80(6):1345-53.

2005

- 201.Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, **Shi FD**. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. **J Immunol.** 2005;174(5):2696-701.
- 202.Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, **Shi FD**. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. **J Immunol.** 2005;175(12):7898-904.
- 203.Megliorino R, **Shi FD**, Peng XX, Wang X, Chan EK, Tan EM, Zhang JY. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. **Cancer Detect Prev.** 2005;29(3):241-8.

- 204.**Shi FD**, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T, Casiano CA, Heeb MJ, Chan EK, Tan EM. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. **Prostate**. 2005;63(3):252-8.
- 2003**
- 205.Kozioł JA, Zhang JY, Casiano CA, Peng XX, **Shi FD**, Feng AC, Chan EK, Tan EM. Recursive partitioning as an approach to selection of immune kers for tumor diagnosis. **Clin Cancer Res**. 2003;9(14):5120-6.
- 2001**
- 206.**Shi FD**, Flodström M, Kim SH, Pakala S, Cleary M, Ljunggren HG, Sarvetnick N. Control of the autoimmune response by type 2 nitric oxide synthase. **J Immunol**. 2001;167(5):3000-6.
- 207.Wang HB, **Shi FD**, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. **J Immunol**. 2001;166(10):6430-6.
- 208.**Shi FD**, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, Sarvetnick N. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. **Proc Natl Acad Sci U S A**. 2001;98(12):6777-82.
- 209.Huang D, **Shi FD**, Giscombe R, Zhou Y, Ljunggren HG, Lefvert AK. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. **Eur J Immunol**. 2001;31(1):225-32.
- 2000**
- 210.**Shi FD**, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG. Natural killer cells determine the outcome of B cell-mediated autoimmunity. **Nat Immunol**. 2000;1(3):245-51.
- 211.Wang HB, **Shi FD**, Li H, van der Meide PH, Ljunggren HG, Link H. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. **Clin Immunol**. 2000;95(2):156-62.
- 212.Wang HB, Li H, **Shi FD**, Chambers BJ, Link H, Ljunggren HG. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. **Int Immunol**. 2000;12(10):1381-8.
- 213.Balasa B, **Shi FD**, Sarvetnick N. Reply to saoudi et al. **Immunol Today**. 2000;21(6):307-8.
- 214.**Shi FD**, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. **J Immunol**. 2000;165(6):3099-104.
- 215.Balasa B, **Shi FD**, Sarvetnick N. Reply to infante, krolick and wall. **Immunol Today**. 2000;21(6):306.
- 1999**
- 216.**Shi FD**, Li H, Wang H, Bai X, van der Meide PH, Link H, Ljunggren HG. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. **J Immunol**. 1999;162(10):5757-63.
- 217.Diab A, Abdalla H, Li HL, **Shi FD**, Zhu J, Höjberg B, Lindquist L, Wretling B, Bakhiet M, Link H. Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. **Infect Immun**. 1999;67(5):2590-601.
- 218.Wang HB, Li H, He B, Bakheit M, Levi M, Wahren B, Berglöf A, Sandstedt K, Link H, **Shi FD**. The role of B-cells in experimental myasthenia gravis in mice. **Biomed Pharmacother**. 1999;53(5-6):227-33.
- 1998**
- 219.**Shi FD**, Bai XF, Li HL, Link H. Macrophage apoptosis in muscle tissue in experimental autoimmune myasthenia gravis. **Muscle Nerve**. 1998;21(8):1071-4.
- 220.Zhang GX, Yu LY, **Shi FD**, Xiao BG, Björk J, Hedlund G, Link H. Cytokine profiles of experimental autoimmune myasthenia gravis after treatment by the synthetic immunomodulator linomide. **Ann N Y Acad Sci**. 1998;841:580-3.
- 221.**Shi FD**, He B, Li H, Matusevicius D, Link H, Ljunggren HG. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. **Eur J Immunol**. 1998;28(11):3587-93.
- 222.Li H, **Shi FD**, Bai X, Huang Y, Diab A, He B, Link H. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. **J Neurol Sci**. 1998;161(1):40-6.

223. **Shi FD**, Bai XF, Xiao BG, van der Meide PH, Link H. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis. **J Neurol Sci.** 1998;155(1):1-12.
224. Xiao BG, Zhang GX, **Shi FD**, Ma CG, Link H. Rease of LFA-1 is associated with upregulation of TGF-beta in CD4(+) T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis. **Clin Immunol Immunopathol.** 1998;89(3):196-204.
225. **Shi FD**, Bai XF, Li HL, Huang YM, Van der Meide PH, Link H. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. **Clin Exp Immunol.** 1998;111(3):506-12.
226. Bai XF, Li HL, **Shi FD**, Liu JQ, Xiao BG, Van der Meide PH, Link H. Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. **Clin Exp Immunol.** 1998;111(1):205-10.
227. Liu JQ, Bai XF, **Shi FD**, Xiao BG, Li HL, Levi M, Mustafa M, Wahren B, Link H. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. **Int Immunol.** 1998;10(8):1139-48.
228. Li H, **Shi FD**, He B, Bakheit M, Wahren B, Berglöf A, Sandstedt K, Link H. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. **Int Immunol.** 1998;10(9):1359-65.
229. Zhang GX, **Shi FD**, Zhu J, Xiao BG, Levi M, Wahren B, Yu LY, Link H. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis. **J Neuroimmunol.** 1998;85(1):96-101.
230. Li HL, **Shi FD**, Bai XF, Huang YM, van der Meide PH, Xiao BG, Link H. Nasal tolerance to experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amounts of interferon-gamma. **Clin Immunol Immunopathol.** 1998;87(1):15-22.

1997

231. Bai XF, **Shi FD**, Zhu J, Xiao BG, Hedlund G, Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. **J Neuroimmunol.** 1997;76(1-2):177-84.
232. **Shi FD**, Zhang GX, Bai XF, Van der Meide PH, Link H. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. **Clin Exp Immunol.** 1997;108(3):523-8.
233. Bai XF, **Shi FD**, Xiao BG, Li HL, van der Meide PH, Link H. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA. **J Neuroimmunol.** 1997;80(1-2):65-75.
234. Zhang GX, Yu LY, **Shi FD**, Xiao BG, Björk J, Hedlund G, Link H. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. **J Neuroimmunol.** 1997;73(1-2):175-82.

Reviews and Commentaries

1. Zhang C, **Shi FD**. Targeting B cells in neuromyelitis optica spectrum disorder. **Lancet Neurol.** 2024;23(6):549-550.
2. Liu Q, Shi K, Wang Y, **Shi FD**. Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke. **Stroke.** 2023;54(10):2688-2697.
3. Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Montalbán X, **Shi FD**, Tintoré M, Xue Q, Yang C, Zhou H. Clinical use of dimethyl fuate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. **Ther Adv Neurol Disord.** 2023;16:17562864231180734.
4. Zhang LJ, Tian DC, Yang L, Shi K, Liu Y, Wang Y, **Shi FD**. White matter disease derived from vascular and demyelinating origins. **Stroke Vasc Neurol.** 2023:svn-2023-002791.
5. Li X, Zhang C, Jia D, Fan M, Li T, Tian DC, Liu Y, **Shi FD**. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis. **Mult Scler Relat Disord.** 2021;53:103030.
6. Sá MJ, Soares Dos Reis R, Altintas A, Celius EG, Chien C, Comi G, Graus F, Hillert J, Hobart J, Khan G, Kissani N, Langdon D, Leite MI, Okuda DT, Palace J, Papais-Alvarenga RM, Mendes-Pinto I, **Shi FD**. State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. **Neurol Ther.** 2020;9(2):281-300.

7. Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, **Shi FD**. Global brain inflammation in stroke. **Lancet Neurol**. 2019;18(11):1058-1066.
8. Shi K, Wood K, **Shi FD**, Wang X, Liu Q. Stroke-induced immunosuppression and poststroke infection. **Stroke Vasc Neurol**. 2018;3(1):34-41.
9. Sreekrishnan A, Dearborn JL, Greer DM, **Shi FD**, Hwang DY, Leasure AC, Zhou SE, Gilmore EJ, Matouk CC, Petersen NH, Sansing LH, Sheth KN. Intracerebral Hemorrhage Location and Functional Outcomes of Patients: A Systematic Literature Review and Meta-Analysis. **Neurocrit Care**. 2016;25(3):384-391.
10. Fu Y, Liu Q, Anrather J, **Shi FD**. Immune interventions in stroke. **Nat Rev Neurol**. 2015;11(9):524-35.
11. Xiao J, Sid AR, **Shi FD**, Hao J. New strategies in the management of Guillain-Barré syndrome. **Clin Rev Allergy Immunol**. 2014;47(3):274-88.
12. Yao Y, Sid AR, **Shi FD**, Hao J. IL-10-producing lymphocytes in inflammatory disease. **Int Rev Immunol**. 2013;32(3):324-36.
13. Shen JX, Qin D, Wang H, Wu C, **Shi FD**, Wu J. Roles of nicotinic acetylcholine receptors in stem cell survival/apoptosis, proliferation and differentiation. **Curr Mol Med**. 2013;13(9):1455-64.
14. **Shi FD**, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. **Nat Rev Immunol**. 2011;11(10):658-71.
15. **Shi FD**, Zhou Q. Natural killer cells as indispensable players and therapeutic targets in autoimmunity. **Autoimmunity**. 2011;44(1):3-10.
16. Cai C, **Shi FD**, Matarese G, La Cava A. Leptin as clinical target. **Recent Pat Inflamm Allergy Drug Discov**. 2009;3(3):160-6.
17. Piao WH, Campagnolo D, Dayao C, Lukas RJ, Wu J, **Shi FD**. Nicotine and inflammatory neurological disorders. **Acta Pharmacol Sin**. 2009;30(6):715-22.
18. Flodström-Tullberg M, Bryceson YT, **Shi FD**, Höglund P, Ljunggren HG. Natural killer cells in human autoimmunity. **Curr Opin Immunol**. 2009;21(6):634-40.
19. La Cava A, Van Kaer L, **Fu-Dong-Shi**. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. **Trends Immunol**. 2006;27(7):322-7.
20. La Cava A, **Shi FD**. Natural and adaptive immune cell-based therapies in autoimmunity. **Curr Med Chem**. 2006;13(13):1557-66.
21. **Shi FD**, Van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T cells. **Nat Rev Immunol**. 2006;6(10):751-60.
22. Tan EM, **Shi FD**. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. **Clin Exp Immunol**. 2003;134(2):169-77.
23. Flodström M, **Shi FD**, Sarvetnick N, Ljunggren HG. The natural killer cell -- friend or foe in autoimmune disease? **Scand J Immunol**. 2002;55(5):432-41.
24. **Shi FD**, Ljunggren HG, Sarvetnick N. Innate immunity and autoimmunity: from self-protection to self-destruction. **Trends Immunol**. 2001;22(2):97-101.

Books and Chapters Edited

In English

1. **Shi FD**. 1998. Immunopathogenesis and Nasal Tolerance in Experimental Autoimmune Myasthenia Gravis. F.D. Shi, and AB Repero-Print, eds. Stockholm. (ISBN 91-628-2995-5)
2. **Shi FD**. 2000. T cell costimulation in myasthenia murine gravis. In Myasthenia Gravis: Disease Mechanisms and Immuno-intervention. P. Christadoss, eds. Narosa Publishing House, New Delhi, NEW, London. (ISBN 81-7319-294-4)
3. **Shi FD** and Sarvetnick N. 2001. Regulation of autoreactive T cells in myasthenia gravis. In Inflammatory events in neurodegeneration. S.C. Bondy, and A. Campbell, eds. Prominent Press, Scottsdale, AZ. 292-307. (ISBN 0-9668997-7-6)
4. **Shi FD**, Campagnolo D, and Vollmer TL.. 2006. Immune therapy in multiple sclerosis: altered peptide ligand and statins. *Shi 06-01-2024*

In "Handbook of Multiple Sclerosis: 4th ed. S.D. Cook, eds. (ISBN 1574448277)

5. Liu R, Hao J, and **Shi FD**. 2009. Regulatory T cells in myasthenia. P. Christadoss, eds. In Myasthenia gravis: Disease mechanisms and immune intervention. Linus Publications, Inc. (ISBN 978-1-60797-060-6)
6. **Shi FD** and Ransohoff RM. 2010. Nature killer cells in the central nervous system. In Nature Killer Cells. M.T. Lotze and A.W. Thomson. Elsevier (ISBN 978-0-12-370454-2)
7. **Shi FD**. 2024. Glia in Multiple sclerosis/ Neuromyelitis optica (NMO). Handbook of Clinical Neurology. Elsevier. Ongoing.

In Chinese

8. Shi QG, Yang L, **Shi FD**. 2011. Pathology of Multiple Sclerosis. In Demyelinating diseases of the nervous system. People's Medical Publishing House (ISBN978-7-117-14985-3).
9. Zhang N, **Shi FD**. 2013. Neuropathy of AIDS. In Neurology. People's Medical Publishing House (ISBN 978-7-117-17235-6).
10. Li T, Shi FD. 2013. Immune pathogenesis of myasthenia gravis. in Myasthenia gravis. People's Medical Publishing House (ISBN978-7-117-19634-5).
11. Wu W, Xue R, **Shi FD**. 2012. Immunology of cerebrovascular disease. In New concept of clinical practice of cerebrovascular disease. Chinese Medical Association continuing medical education materials. People's Military Medical Publishing House (ISBN 978-7-5091-5978-1).
12. **Shi FD**, Gong FL. 2014. Central nervous immunity. In Medical immunology. People's Medical Publishing House (ISBN 978-7-03-041594-3).
13. Yang L, **Shi FD**. 2018. Neurology. General higher education "13th Five-Year Plan" textbook, national higher medical college planning textbook. Tsinghua University Press (ISBN978-7-302-51073-4).
14. Pan J, **Shi FD**. 2024. Neurology. The ninth edition of the Textbooks for Clinical majors for National Colleges and Universities (Five-Year). People's Medical Publishing House. Ongoing.